J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal
Johnson & Johnson said on Monday it would buy neurological drugmaker Intra-Cellular Therapies for $14.6 billion, its biggest ...
J&J buys Intra-Cellular in $14.6B deal, delving into central nervous system disorders
Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by ...
Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal
Johnson & Johnson agreed to acquire mental-illness drug developer Intra-Cellular Therapies for about $15 billion.